A5029163669- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Health and Medical Studies
- Statistical Methods in Clinical Trials
- Diabetes Management and Education
- Chronic Disease Management Strategies
- Healthcare cost, quality, practices
- Medical and Health Sciences Research
- Economic and Financial Impacts of Cancer
- Clinical practice guidelines implementation
- Coronary Interventions and Diagnostics
- Healthcare Policy and Management
- Hepatitis C virus research
- Pain Management and Placebo Effect
- Mental Health Treatment and Access
- Peripheral Artery Disease Management
- Biosimilars and Bioanalytical Methods
- Vaccine Coverage and Hesitancy
- Cerebrovascular and Carotid Artery Diseases
- Physical Activity and Health
- Global Health Care Issues
- Medical Practices and Rehabilitation
- Biomedical Ethics and Regulation
- Schizophrenia research and treatment
Heinrich Heine University Düsseldorf
2015-2025
Düsseldorf University Hospital
2021-2023
Deutsches Diabetes-Zentrum e.V.
2016-2021
Bayer (Germany)
2015-2020
Institute of Health Services and Policy Research
2018
German Center for Diabetes Research
2016
Federal Union of German Associations of Pharmacists
2012-2014
Institute for Quality and Efficiency in Health Care
2008-2012
Medizinische Hochschule Hannover
2004-2010
Osaka City University
2006
Background: Patient involvement is widely acknowledged to be a valuable component in health technology assessment (HTA) and healthcare decision making. However, quantitative approaches ascertain patients' preferences for treatment endpoints are not yet established. The objective of this study introduce the analytic hierarchy process (AHP) as preference elicitation method HTA. Based on systematic literature review use AHP care 2009, German Institute Quality Efficiency Health Care (IQWiG)...
Since the introduction of German health care reform in January 2011, an early benefit assessment (EBA) is required for all new medicines. Pharmaceutical manufacturers have to submit a dossier evaluation by Institute Quality and Efficiency Health Care (IQWiG). A final decision made Federal Joint Committee (G-BA). The aim this investigation was analyse outcomes 18 months after legislation identify critical areas requiring further discussion development. All EBAs commenced prior June 2012 were...
Background: Comprehensive health technology assessments (HTAs) include thorough reflections on ethical issues associated with technologies, their use, and value-based decisions in the assessment process. As methods of information retrieval for effectiveness are not applicable to issues, a specific methodological approach is necessary. Objectives: In absence existing adapted methods, our objective was develop systematic related technologies. Method Results: A literature search conducted...
Das Deutsche Netzwerk Versorgungsforschung e. V. (DNVF V.) hat am 30.08.2010 getragen von den genannten im DNVF organisierten Fachgesellschaften und Organisationen, das Memorandum III "Methoden für die Versorgungsforschung" Teil 2 verabschiedet, in dieser Zeitschrift publiziert wurde [Gesundheitswesen 2010; 72: 739–748]. Die vorliegende Publikation fokussiert auf Methodik der ökonomischen Evaluation Gesundheitstechnologien bzw. Interventionen stellt eine Vertiefung zu dem dar. Zunächst...
In Germany, all new drugs undergo an early benefit assessment (EBA) by the decision-making body (G-BA). Due to limited access clinical data in pediatric healthcare since 2017, evidence transfer has allowed for from adult studies be used EBA of drugs. This study examines acceptance transfer, aiming understand its correlation with granted added benefit. By searching G-BA database, relevant EBAs were identified. addition descriptive statistics, agreement statistics regarding binary and ordinal...
The majority of nursing home residents with dementia experience behavioural and psychological symptoms like apathy, agitation, anxiety. According to analyses prescription prevalence in Germany, antipsychotic drugs are regularly prescribed as first-line treatment neuropsychiatric persons dementia, although guidelines clearly prioritise non-pharmacological interventions. Frequently, for inappropriate reasons too long without regular reviewing. use antipsychotics is associated adverse events...
In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration. The purpose of this study was identify drivers negotiated (including arbitrated) prices non-orphan in Germany.The analysis considered drugs that underwent a appraisal between January 2011 June 2016, displayed reimbursement Drug Directory (Lauer-Taxe®) November 2017. Negotiated annual treatment costs were...
In Germany, a mandatory early benefit assessment (EBA) by the Federal Joint Committee (G-BA) is required for reimbursement of new marketing-authorised medicines. Additional based on patient-relevant endpoints in mortality, morbidity and health-related quality life (HRQoL). We aimed to compare related categories used marketing authorisation those considered G-BA field oncology.We evaluated EBAs oncology commencing prior 31 December 2013. Endpoints appropriate medicines, derived from European...
Objective: To assess a comprehensive multicomponent intervention against low intensity for promoting physical activity in chronic back pain patients. Design: Randomised controlled trial. Setting: Inpatient rehabilitation and aftercare. Subjects: A total of 412 patients with pain. Interventions: (Movement Coaching) comprising small group (twice during inpatient rehabilitation), tailored telephone aftercare after rehabilitation) internet-based (web 2.0 platform) versus level (two general...
Physical restraints such as bedrails and belts are regularly applied in German nursing homes despite clear evidence showing their lack of effectiveness safety. In a cluster-randomised controlled trial, the efficacy safety guideline-based multicomponent intervention programme has been proven. The present study aims to evaluate two different versions original home residents four regions throughout Germany.The is pragmatic trial comparing groups, i.e. (1) updated (2) concise version programme,...
OBJECTIVE Increased health care use and costs have been reported in individuals with diabetes comorbid depression. Knowledge regarding cost differences between alone those diagnosed/undiagnosed depression is, however, scarce. We therefore compared for patients no documented diagnosis or self-reported symptoms several components, including mental costs. RESEARCH DESIGN AND METHODS Data from a 2013 cross-sectional survey of randomly sampled members nationwide German statutory insurance (SHI)...
Abstract The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per social code, EBA is based on registration trials and evaluation of the patient-relevant effect new medicines compared to an appropriate comparator as defined by Federal Joint Committee (G-BA). Current decisions released have unveiled issues regarding acceptance some endpoints G-BA IQWiG are grading endpoints, focusing overall survival preferred endpoint in oncology. A taskforce...
Cost-of-illness (CoI) studies are important instruments for estimating the socioeconomic burden of specified diseases. CoI provide information about cost structure a disease, resulting research need, approaches to improve aspects care and, monetary consequences from different perspectives. This can be useful healthcare and health policy. Due heterogeneity available Cost-of-Illness studies, working group 'Health Economics' German Network Healthcare Research (DNVF) in accordance with Society...
According to the AMNOG act, German Federal Joint Committee (G-BA) determines additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from market at any time during process. This analysis aims compare recommendations in clinical guidelines and HTA appraisals that were withdrawn since introduction 2011. Medications between January 2011 June 2016 following assessment categorized opt-outs (max. 2 weeks after start...
In Germany, starting in 2011, legislation gave new critical importance to benefit assessments through the Act on Reform of Market for Medicinal Products (Arzneimittelneuordnungsgesetz [AMNOG]) [1Federal Ministry Health. The (Gesetz zur Neuordnung des Arzneimittelmarktes - AMNOG). Available from: http://www.bmg.bund.de/ministerium/english-version/health/amnog.html. [Accessed November 22, 2013].Google Scholar, 2Ruof J. Schwartz F.W. Schulenburg J.M. Dintsios C.M. Early assessment (EBA)...